ETF Managers Trust ETFMG Prime 2X Daily Junior Silver Miners Fund SILX 深 滬

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Silexion Therapeutics announced successful preclinical data for SIL204, demonstrating effective distribution to liver, peritoneum, and lungs, with measurable tumor burden reductions. The study validates the systemic component of their dual-route administration strategy, targeting both primary tumors and metastatic disease. Silexion plans to initiate Phase 2/3 trials in H1 2026, following regulatory submissions in Q4 2025 and Q1 2026.

09-11 11:00